Verve Therapeutics Inc (VERV)

34.92 +1.77  +5.34% NASDAQ Nov 29, 13:16 USD

Verve Therapeutics Cash from Investing (TTM):

-170.23M for Sept. 30, 2021
View 4,000+ financial data types
View Full Chart

Cash from Investing (TTM) Chart

Export Data
Save Image
Print Image

Historical Cash from Investing (TTM) Data

View and export this data going back to 2020. Start your Free Trial
Export Data Date Range:
Data for this Date Range  
Sept. 30, 2021 -170.23M
June 30, 2021 39.37M
March 31, 2021 -48.05M
Dec. 31, 2020 -51.13M

There is no data for the selected date range.

An error occurred. Please try again by refreshing your browser or contact us with details of your problem.


Cash From Investing Definition

Cash from Investing is a major line item of the statement of cash flows. This metric tracks the movement of cash flows for the overall investing activities of the company. A few examples of investing activities include net change in PP&E, and net divestitures.

Read full definition.

Cash from Investing (TTM) Benchmarks

Regenxbio Inc -178.71M
Krystal Biotech Inc -106.45M
Beam Therapeutics Inc -298.08M

Cash from Investing (TTM) Range, Past 5 Years

Minimum -170.23M Sep 2021
Maximum 39.37M Jun 2021
Average -57.51M


Verve Therapeutics' Q3 Net Loss Shrinks
MT Newswires 11/10 07:51 ET
Top IPO additions to Russell 2000 Index
SA Breaking News 09/17 10:48 ET



Please note that this feature is only available as an add-on to YCharts subscriptions.

Please note that this feature requires full activation of your account and is not permitted during the free trial period.

Start My Free Trial {{}} No credit card required.

Already a subscriber? Sign in.